CN1919277B - 一种药物组合物在制备增强胰岛素敏感性药物中的应用 - Google Patents
一种药物组合物在制备增强胰岛素敏感性药物中的应用 Download PDFInfo
- Publication number
- CN1919277B CN1919277B CN2005100148300A CN200510014830A CN1919277B CN 1919277 B CN1919277 B CN 1919277B CN 2005100148300 A CN2005100148300 A CN 2005100148300A CN 200510014830 A CN200510014830 A CN 200510014830A CN 1919277 B CN1919277 B CN 1919277B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- group
- rhizoma
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 96
- 102000004877 Insulin Human genes 0.000 claims description 49
- 108090001061 Insulin Proteins 0.000 claims description 49
- 229940125396 insulin Drugs 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 239000008517 radix Trichosanthis Substances 0.000 claims description 18
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 9
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 9
- 241000207929 Scutellaria Species 0.000 claims description 9
- 241001522129 Pinellia Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000758993 Equisetidae Species 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 241000700159 Rattus Species 0.000 description 28
- 239000000284 extract Substances 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
- 239000002775 capsule Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 238000001291 vacuum drying Methods 0.000 description 11
- 230000006837 decompression Effects 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000004064 recycling Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000010135 fructus aurantii immaturus Substances 0.000 description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 201000008980 hyperinsulinism Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000021590 normal diet Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000003390 Chinese drug Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
- 229940062310 avandia Drugs 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000080 chela (arthropods) Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- GDEBSAWXIHEMNF-UHFFFAOYSA-O cupferron Chemical compound [NH4+].O=NN([O-])C1=CC=CC=C1 GDEBSAWXIHEMNF-UHFFFAOYSA-O 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
分组 | 例数(只) | 肝脏甘油三脂(mg/g) | 肌肉甘油三脂(mg/g) |
正常组 | 8 | 29.44±3.24## | 13.4±2.31 |
模型组 | 9 | 41.51±6.42** | 22.9±7.87# |
饮食控制组 | 9 | 34.62±7.25 | 17.2±4.54 |
文迪雅组 | 8 | 28.64±6.71** | 15.8±5.12 |
降糖颗粒组 | 9 | 25.94±4.65** | 16.4±3.19 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100148300A CN1919277B (zh) | 2005-08-24 | 2005-08-24 | 一种药物组合物在制备增强胰岛素敏感性药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100148300A CN1919277B (zh) | 2005-08-24 | 2005-08-24 | 一种药物组合物在制备增强胰岛素敏感性药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1919277A CN1919277A (zh) | 2007-02-28 |
CN1919277B true CN1919277B (zh) | 2011-11-30 |
Family
ID=37777214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100148300A Active CN1919277B (zh) | 2005-08-24 | 2005-08-24 | 一种药物组合物在制备增强胰岛素敏感性药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1919277B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101357183B (zh) * | 2007-08-02 | 2011-11-30 | 天津天士力制药股份有限公司 | 一种含有枳实的治疗糖尿病的药物及其制备方法 |
-
2005
- 2005-08-24 CN CN2005100148300A patent/CN1919277B/zh active Active
Non-Patent Citations (5)
Title |
---|
仝小林.降糖心悟.《中国医药学报》.2004,第19卷(第1期),36. * |
吕兰薰.单味中草药降血糖作用的研究.《陕西中医学院学报》.1992,第15卷(第3期),35-39. * |
李慧金等.小方单方治疗糖尿病近况.《山东中医学院学报》.1996,第20卷(第5期),353-356. * |
柳红芳.仝小林应用仲景方治疗糖尿病的经验.《北京中医药大学学报》.2001,第24卷(第1期),51-53. * |
柳红芳等.开郁清胃颗粒治疗型糖尿病胃动力障碍52例临床观察.《中国实验方剂学杂志》.2002,第8卷(第6期),53-55. * |
Also Published As
Publication number | Publication date |
---|---|
CN1919277A (zh) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103285231A (zh) | 一种用于糖尿病辅助治疗的药物组合物及其制法 | |
CN101878906B (zh) | 一种具有辅助降血糖功能的保健食品及其制备方法 | |
CN101164585B (zh) | 一种治疗痛风的药物及其制备方法 | |
CN115364170B (zh) | 一种糖代谢调节剂及其制备方法和应用 | |
CN101947296A (zh) | 一种治疗糖尿病的中药组合物 | |
KR20010029771A (ko) | 당뇨병 치료제용 한방약 복방제제 | |
CN1919277B (zh) | 一种药物组合物在制备增强胰岛素敏感性药物中的应用 | |
CN104137992A (zh) | 一种降血糖保健食品及其制备方法 | |
CN102028703B (zh) | 菊粉的新用途 | |
CN100496561C (zh) | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及其制备方法 | |
CN110025709B (zh) | 一种苓术山药散的制备方法及其应用 | |
CN108042710B (zh) | 一种治疗气阴两虚兼湿热内蕴型2型糖尿病的中药组合物及其应用 | |
WO2010037255A1 (zh) | 一种人参绞股蓝复方制剂在制备调节血脂、血糖的药物中的用途 | |
CN106344600A (zh) | 橙皮苷的新用途及含有橙皮苷的药物组合物 | |
CN101491629A (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
CN101204504A (zh) | 一种防治糖尿病的药物组合物及其制备方法 | |
CN101120969A (zh) | 一种治疗糖尿病及其并发症的药物及其制备方法 | |
CN105434886A (zh) | 一种具有降血糖作用的铁皮石斛根提取物及其用途 | |
CN115779046B (zh) | 一种防治糖尿病的中药组合物、中药制剂与应用 | |
CN108704036A (zh) | 一种治疗痛风的复方中药制剂及其制备方法 | |
CN103230552A (zh) | 一种治疗糖尿病的中药 | |
CN101618157B (zh) | 一种用于治疗秋燥感冒的药物组合物及其制备方法 | |
CN103656161B (zh) | 一种中药组合物及其制备方法和用途 | |
CN101491581A (zh) | 一种具有降血糖功能的组合物及其制备方法 | |
CN102048132A (zh) | 一种用于降血糖的保健食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220607 Address after: 101-1032, F1, building 3, No. 103, Beiqing Road, Haidian District, Beijing 100081 Patentee after: Beijing zhongyitang Technology Co.,Ltd. Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right |